2026 FDA Pharmaceutical Companies 
European Pharmaceutical Review
SEPTEMBER 12, 2023
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.
STAT
AUGUST 22, 2023
German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 28, 2023
The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Key among them has been the extension of Syngene’s research collaboration with leading biotech company Amgen Inc. until 2026.
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. The scope of the problem.
The Checkup by Singlecare
JUNE 6, 2024
Farxiga (dapagliflozin) is a brand-name prescription medication that has been approved by the Food & Drug Administration (FDA) for several indications. This law enables Medicare to negotiate directly with pharmaceutical companies, which should ultimately result in lower prescription drug costs for consumers.
The Checkup by Singlecare
JUNE 6, 2024
Jardiance is a brand-name drug that was initially approved by the Food and Drug Administration (FDA) to control blood sugar in adults with Type 2 diabetes. The law will allow Medicare to negotiate directly with pharmaceutical companies to improve access to affordable prescription drug costs.
PharmaShots
FEBRUARY 21, 2023
With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.
Expert insights. Personalized for you.
105 
Let's personalize your content